DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for benign spiradenoma — screening already-approved drugs against its 13-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign spiradenoma maps to a 13-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign spiradenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
AKT serine/threonine kinase 1 (AKT1) — AKT1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet propanoylaminodrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7NH5 · 1.9 Å · ligand ~{N}-methyl-6-[4-[[4-[2-oxidanylidene-6-(propanoylamino)-3~{H}-benzimidazol-1-yl]piperidin-1-yl]methyl]phenyl]-5-phenyl-pyridine-3-carboxamide (UC8). Experimental structure, not a prediction.
What the evidence adds up to
Benign spiradenoma is a cutaneous adnexal tumour. A 1994 report described a 16-year-old girl with multiple lesions present at birth in a linear nevoid pattern on the right half of her body, involving the periorbital region, cheek, neck, trunk, thigh, and leg. Only a few nodules were slightly painful. No family members had similar lesions. Excisional biopsies of three lesions confirmed benign spiradenoma histologically, and in some areas the tumour was directly connected to a pilosebaceous unit.
A 2010 report described a 60-year-old man with a spiradenoma on the right temple in which an adenomyoepitheliomatous component comprised approximately 75% of the tumour. The authors noted that lymphocytes, an essential constituent of spiradenoma, were markedly diminished or absent in these adenomatous areas. Some glandular structures showed intraluminal bridging or a cribriform appearance, and there were foci of squamous and clear cell metaplasia. The authors warned that such unusual features can cause diagnostic difficulty, including confusion with malignant transformation, and suggested that one pathway of malignant transformation in spiradenomas may proceed through adenomatous and atypical adenomatous change to adenocarcinoma in situ and invasive adenocarcinoma.
A 2015 case report described a 60-year-old man with a tender plaque on the chest for ten years, in which multiple painful nodules appeared within the plaque over one month and rapidly increased in size. This was diagnosed as spiradenocarcinoma arising from a long-standing plaque-like spiradenoma, with overlapping histological features of adenoid cystic carcinoma. The patient denied any personal or family history of cutaneous lesions.
No clinical trials, no drug interventions, and no treatment outcomes for benign spiradenoma are reported in these abstracts. What is missing is any systematic investigation of medical therapy for this condition, including any trial design, patient stratification, or funding for such research.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Dermatopathology · 1994 · 34 citations
Multiple Nevoid Spiradenomas
AbstractThis report delineates a new clinical presentation of multiple benign spiradenoma (BS), a diffuse linear nevoid pattern. A 16-year-old girl, in otherwise good health, had many papulonodular lesions, varying in color from blue-gray to bright red, disposed linearly on the right half of her body, involving the periorbital region, cheek, lateral side of the neck, trunk, linea alba, right thigh, and leg. Only a few nodules were slightly painful. Lesions were reported to be present at birth; no family members had similar lesions, either in solitary or multiple form. Excisional biopsies of three lesions from the neck, abdomen, and leg, respectively, were performed; histologically, all three samples showed a picture of BS. In some areas, the tumor was directly connected to a pilosebaceous unit. Furthermore, a focal area with pilar differentiation at the periphery of the lobules was observed, which might suggest that BS can differentiate toward various cutaneous adnexal structures. Our patient probably is the first one reported with diffuse linear nevoid lesions of BS, present at birth and involving the right half of the body.
American Journal of Dermatopathology · 2010 · 4 citations
Spiradenoma With Marked Adenomyoepitheliomatous Features
AbstractTo the Editors: In 2008, we reported a series of 5 cases of spiradenoma and 1 case of spiradenocylindroma that, in addition to areas of a conventional growth, manifested an adenomatous component consisting of compactly situated well-developed glands having small round lumens lined by inner pale to eosinophilic cells and surrounded by an outer well-formed peripheral layer of myoepithelial cells.1 Lymphocytes, an essential constituent of a spiradenoma, were markedly diminished or absent in the adenomatous areas. In 4 of those 6 cases, the adenomatous component was a minor but significant portion of the tumors, but in 2 cases, it was quite prominent, comprising approximately 20% of the tumor area.1 We have recently encountered a case of spiradenoma in a 60-year-old male patient located on the right temple with an unduly marked adenomatous (adenomyoepitheliomatous) moiety, which clearly dominated over the conventional portion of the neoplasm, comprising in as much as 75% (Fig. 1A, B). As in the original neoplasms, each glandular structure was surrounded by a well-developed peripheral layer of myoepithelial cells, which stained for S-100 protein and alpha smooth muscle actin (Fig. 1C, D). These areas and myoepithelial differentiation were so prominent that one can speak of “adenomyoepitheliomatous” areas instead of a mere “adenomatous” component. The adenomyoepitheliomatous areas were identical to those seen in adenomyoepitheliomas in various organs. Apart from the prominence of the adenomyoepitheliomatous compartment, the present case manifested some other features that were neither observed in our previous report nor in that of Michal2 who described the first occurrence of well-developed glands in spiradenoma. Namely, albeit usually being simple with round lumina, some glandular structures in the present case manifested a more complex appearance, with intraluminal bridging or, occasionally, cribriform features (Fig. 1E, F). Additionally, there were multiple foci with squamous metaplasia and intraglandular clear cell metaplasia (Fig. 1G), and in some areas, it was evident that the squamous metaplastic epithelium is closely associated with the glandular elements.FIGURE 1: Spiradenoma (A) with a prominent and dominant adenomyoepitheliomatous component highlighted by alpha smooth muscle actin (B); glands with a well-developed peripheral myoepithelial cell layers adjacent to conventional areas of spiradenoma (C); peripheral myoepithelial cell layers highlighted by alpha smooth muscle actin (D); occasional glands demonstrating intraluminal bridging (E) and a cribriform appearance (F); and areas with squamous metaplasia. G, Clear cell change within some lumina.This case with unduly prominent adenomyoepitheliomatous differentiation further underscores diagnostic difficulties that may be caused by an unusual example of spiradenoma. It was sent in consultation with differential diagnostic considerations that included, among others, malignant transformation. Indeed, some malignant tumors arising within preexisting spiradenoma may manifest similar adenomatous areas, including adenocarcinoma in situ or invasive adenocarcinoma.3 In our original series on spiradenomas with an adenomatous component, there was one case with clearly atypical adenomatous component, which together with subsequent observations of invasive adenocarcinoma arising from benign spiradenoma suggests that one of the pathways of malignant transformation in spiradenomas may be via a sequence of adenomatous and atypical adenomatous change, adenocarcinoma in situ, and, ultimately, invasive adenocarcinoma.3 Denisa Kacerovska, MD, PhD Dmitry V. Kazakov, MD, PhD Sikl's Department of Pathology, Medical Faculty Hospital, Charles University, Pilsen, Czech Republic Heinz Kutzner, MD, PhD Dermatohistopathologische Gemeinschaftspraxis, Friedrichshafen, Germany Michal Michal, MD Sikl's Department of Pathology, Medical Faculty Hospital, Charles University, Pilsen, Czech Republic, Bioptical Laboratory, Pilsen, Czech Republic
European Journal of Dermatology · 2015 · 3 citations
A rare case of spiradenocarcinoma with features of adenoid cystic carcinoma
AbstractSpiradenocarcinoma is characterized by the rapid enlargement of a pre-existing benign spiradenoma. Herein, we report a case of spiradenocarcinoma arising from a long-standing plaque-like spiradenoma with overlapping histological features of adenoid cystic carcinoma (ACC).We report a 60-year-old man with a tender plaque on the chest for ten years. One month ago, multiple painful nodules appeared within the plaque and rapidly increased in size. The patient denied any personal or family history of cutaneous [...]
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
